Preview

Медицинская иммунология

Расширенный поиск

ИММУНОМОДУЛИРУЮЩАЯ АКТИВНОСТЬ МЕЗЕНХИМАЛЬНЫХ СТРОМАЛЬНЫХ (СТВОЛОВЫХ) КЛЕТОК

https://doi.org/10.15789/1563-0625-2014-2-107-126

Полный текст:

Аннотация

Мезенхимальными стромальными, или стволовыми, клетками (МСК) называют примитивные фибробластоподобные клетки, способные дифференцироваться в элементы соединительной ткани (остеоциты, хондроциты, адипоциты), скелетных мышц и кровеносных сосудов. В обзоре изложены современные представления о происхождении МСК, их иммунофенотипе и иммуногенности. Изучаемая в течение последних 10 лет способность МСК выступать в качестве модуляторов иммунного ответа проявляется в подавлении активности факторов врожденного иммунитета (дендритных клеток, естественных киллеров, комплемента), функций цитотоксических Т-лимфоцитов и Т-хелперов, а также в активации регуляторных Т-клеток. Особое внимание уделено анализу противоречивых сведений о влиянии МСК на активность В-лимфоцитов и плазматических клеток-продуцентов антител в экспериментах in vitro и in vivo. Имеющиеся данные не позволяют объяснить выявленные противоречия. В будущих исследованиях следует учитывать принадлежность В-лимфоцитов к субпопуляциям В1а, В1b или В2-клеток, существование среди них малоизученных регуляторных В-лимфоцитов, а также возможную гетерогенность исходных культур МСК, получаемых в соответствии с первоначально принятыми протоколами.

Об авторе

В. Б. Климович
ФГБУ «Российский научный центр радиологии и хирургических технологий» Министерства здравоохранения РФ, Санкт-Петербург
Россия

д.м.н., профессор, руководитель лаборатории гибридомной технологии ФГБУ «Российский научный центр радиологии и хирургических технологий» Министерства здравоохранения РФ, Санкт-Петербург



Список литературы

1. Kruglyakov P.V., Lokhmatova E.L., Klimovich V.B., Zaritskiy A.Yu. Mezenkhimnye stvolovye kletki i immunopatologicheskie sostoyaniya organizma [Mesenchymal Stem Cells and Immunopathologic Conditions of a Human Body]. Kletochnaya transplantologiya i tkanevaya inzheneriya – Cellular Transplantology and Tissue Engeneering, 2006, vol. 1, no. 3 (5), pp. 36-41.

2. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 2005, vol. 105, pp. 1815-1822.

3. Amé-Thomas P., Maby-El Hajjami H., Monvoisin C., Jean R., Monnier D., Caulet-Maugendre S., Guillaudeux T., Lamy T., Fest T., Tarte K. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood, 2007, vol. 109, pp. 693-702.

4. Ankrum J., Karp J.M. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol. Med., 2010, vol. 16, pp. 203-209.

5. Asari S., Itakura S., Ferreri K., Liu C.P., Kuroda Y., Kandeel F., Mullen Y. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp. Hematol., 2009, vol. 37, pp. 604-615.

6. Augello A., Tasso R., Negrini S.M., Amateis A., Indiveri F., Cancedda R., Pennesi G. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur .J. Immunol., 2005, vol. 35, pp. 1482-1490.

7. Bacchetta R., Passerini L., Gambineri E., Dai M., Allan S.E., Perroni L., Dagna-Bricarelli F., Sartirana C., Matthes-Martin S., Lawitschka A., Azzari C., Ziegler S.F., Levings M.K., Roncarolo M.G. Defective regulatory and effector T cell functions in patients with FoxP3 mutations. J. Clin. Invest., 2006, vol. 116, pp. 713-722.

8. Barry F., Boynton R., Murphy M., Haynesworth S., Zaia J. The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem. Biophys. Res. Commun., 2001, vol. 289, pp. 519-524.

9. Barry F.P., Murphy J.M., English K., Mahon B.P. Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev., 2005, vol. 14, pp. 252-265.

10. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., Hardy W., Devine S., Ucker D., Deans R., Moseley A., Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol., 2002, vol. 30, pp. 42-48.

11. Batten P., Sarathchandra P., Antoniw J.W., Tay S.S., Lowdell M.W., Taylor P.M., Yacoub M.H. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng., 2006, vol. 12, pp. 2263-2273.

12. Bestard O., Cruzado J.M., Mestre M., Cald s A., Bas J., Carrera M., Torras J., Rama I., Moreso F., Ser n D., Grinyó J.M. Achieving donor-specific hyporesponsiveness is associated with FoxP3+ regulatory T cell recruitment in human renal allograft infiltrates. J. Immunol., 2007, vol. 179, pp. 4901-4909.

13. Beyth S., Borovsky Z., Mevorach D., Liebergall M., Gazit Z., Aslan H., Galun E., Rachmilewitz J. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood, 2005, vol. 105, pp. 2214-2219.

14. Bianco P., Gehron R.P. Marrow stromal stem cells. J. Clin. Invest., 2000, vol. 105, pp. 1663-1668.

15. Bocelli-Tyndall C., Bracci L., Spagnoli G., Braccini A., Bouchenaki M., Ceredig R., Pistoia V., Martin I., Tyndall A. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford), 2007, vol. 46, pp. 403-408.

16. Bochev I., Elmadjian G., Kyurkchiev D., Tzvetanov L., Altankova I., Tivchev P., Kyurkchiev S. Mesenchymal stem cells from human bone marrow or adipose tissue differently modulate mitogen-stimulated B-cell immunoglobulin production in vitro. Cell Biol. Int., 2008, vol. 32, pp. 384-393.

17. Boumaza I., Srinivasan S., Witt W.T., Feghali-Bostwick C., Dai Y., Garcia-Ocana A., Feili-Hariri M. Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J. Autoimmun., 2009, vol. 32, pp. 333-342.

18. Bruder S. P., Jaiswal N. Haynesworth S. E. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J. Cell. Biochem., 1997, vol. 64, pp. 278-294.

19. Campagnolo P., Cesselli D., Al Haj Zen A., Beltrami A.P., Kr nkel N., Katare R., Angelini G., Emanueli C., Madeddu P. Human adult vena saphena contains perivascular progenitor cells endowed with clonogenic and proangiogenic potential. Circulation, 2010, vol. 121, no. 15, pp. 1735-1745.

20. Caplan A.I. All MSCs are pericytes? Cell Stem Cell, 2008, vol. 3, pp. 229-230.

21. Casiraghi F., Azzollini N., Cassis P., Imberti B., Morigi M., Cugini D., Cavinato R.A., Todeschini M., Solini S., Sonzogni A., Perico N., Remuzzi G., Noris M. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J. Immunol., 2008, vol. 181, pp. 3933-3946.

22. Choi E.W., Shin I.S., Park S.Y., Park J.H., Kim J.S., Yoon E.J., Kang S.K., Ra J.C., Hong S.H. Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum., 2012, vol. 64, pp. 243-253.

23. Clark L.B., Appleby M.W., Brunkow M.E., Wilkinson J.E., Ziegler S.F., Ramsdell F. Cellular and molecular characterization of the scurfy mouse mutant. J. Immunol., 1999, vol. 162, pp. 2546-2554.

24. Cognet P.A., Minguell J.J. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J. Cell. Physiol., 1999, vol. 181, pp. 67-73.

25. Comoli P., Ginevri F., Maccario R., Avanzini M.A., Marconi M., Groff A., Cometa A., Cioni M., Porretti L., Barberi W., Frassoni F., Locatelli F.. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant., 2008, vol. 23, pp. 1196-1202.

26. Cook D.N., Prosser D.M., Forster R., Zhang J., Kuklin N.A., Abbondanzo S.J., Niu X.D., Chen S.C., Manfra D.J., Wiekowski M.T., Sullivan L.M., Smith S.R., Greenberg H.B., Narula S.K., Lipp M., Lira S.A. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity, 2000, vol. 12, pp. 495-503.

27. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., Risso M., Gualandi F., Mancardi G.L., Pistoia V., and Uccelli A. Human mesenchymal stem cells modulate B-cell functions. Blood, 2006, vol. 107, pp. 367-372.

28. Crisan M., Yap S., Casteilla L., Chen C.W., Corselli M., Park T.S., Andriolo G., Sun B., Zheng B., Zhang L., Norotte C., Teng P.N., Traas J., Schugar R., Deasy B.M., Badylak S., Buhring H.J., Giacobino J.P., Lazzari L., Huard J., Péault B. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell, 2008, vol. 3, pp. 301-313.

29. Crop M.J., Baan C.C., Korevaar S.S., Ijzermans J.N., Weimar W., Hoogduijn M.J. Human adipose tissuederived mesenchymal stem cells induce explosive T-cell proliferation. Stem Cells Dev., 2010, vol. 19, pp. 1843-1853.

30. da Silva Meirelles L., Chagastelles P.C., Nardi N.B. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci., 2006, vol. 119, pp. 2204-2013.

31. Dazzi F., Ramasamy R., Glennie S., Jones S.P., Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev., 2006, vol. 20, pp. 161-171.

32. Deans R.J., Moseley A.B. Mesenchymal stem cells. Biology and potential clinical uses. Exp. Hematol., 2000, vol. 28, pp. 875-884.

33. DelaRosa O., Lombardo E. Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential. BMC Mediators Inflamm., 2010, 865601.

34. DelaRosa O., S nchez-Correa B., Morgado S., Ram rez C., del R o B., Menta R., Lombardo E., Tarazona R., Casado J.G. Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis. Stem Cells Dev., 2012, vol. 21, pp. 1333-1343.

35. Di Ianni M., Del Papa B., De Ioanni M., Moretti L., Bonifacio E., Cecchini D., Sportoletti P., Falzetti F., Tabilio A. Mesenchymal cells recruit and regulate T regulatory cells. Exp. Hematol., 2008, vol. 36, pp. 309-318.

36. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S., Gianni A.M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 2002, vol. 99, pp. 3838-3843.

37. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., Noël D., Jorgensen C. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood, 2003, vol. 102, pp. 3837-3844.

38. Djouad F., Charbonnier L.M., Bouffi C., Louis-Plence P., Bony C., Apparailly F., Cantos C., Jorgensen C., Noel D. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells, 2007, vol. 25, pp. 2025-2032.

39. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 2006, vol. 8, pp. 315-317.

40. Engela A.U., Baan C.C., Peeters A.M., Weimar W., Hoogduijn M.J. Interaction between adipose issue derived mesenchymal stem cells and regulatory T cells. Cell Transplant., 2013, vol. 22, pp. 41-54.

41. English K., Barry F.P., Field-Corbett C.P., Mahon B.P. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol. Lett., 2007, vol. 110, pp. 91-100.

42. English K., Barry F.P., Mahon B.P. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol. Lett., 2008, vol. 115, pp. 50-58.

43. Fontenot J.D., Gavin M.A., Rudensky A.Y. FoxP3 programs the development and function of CD4+CD25+regulatory T cells. Nat. Immunol., 2003, vol. 4, pp. 330-336.

44. Friedenstein A.J., Petrakova K.V., Kurolesova A.I., Frolova G.P. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation., 1968, vol. 6, pp. 230-247.

45. Ge W., Jiang J., Baroja M.L., Arp J., Zassoko R., Liu W., Bartholomew A., Garcia B., Wang H. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am. J. Transplant., 2009, vol. 9. pp. 1760-1772.

46. Geissmann F., Manz M.G., Jung S., Sieweke M.H., Merad M., Ley K. Development of monocytes, macrophages, and dendritic cells. Science, 2010, vol. 327, pp. 656-661.

47. Gerdoni E., Gallo B., Casazza S., Musio S., Bonanni I., Pedemonte E., Mantegazza R., Frassoni F., Mancardi G., Pedotti R., Uccelli A. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann. Neurol., 2007, vol. 61, pp. 219-227.

48. Gershon R. K., Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology, 1970, vol. 18, pp. 723-737.

49. Ghannam S., Pene J., Torcy-Moquet G., Jorgensen C., Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol., 2010, vol. 185, pp. 302-312.

50. Glennie S., Soeiro I., Dyson P.J., Lam E.W., Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood, 2005, vol. 105, pp. 2821-2827.

51. Gray D., Gray M. What are regulatory B cells? Eur. J. Immunol., 2010, vol. 40, pp. 2677-2679.

52. Griffin M.D., Ritter T. Mahon B.P. Immunological Aspects of Allogeneic Mesenchymal Stem Cell Therapies. Human Gene Therapy, 2010, vol. 21, pp. 1641-1655.

53. Gu Z., Akiyama K., Ma X., Zhang H., Feng X., Yao G., Hou Y., Lu L., Gilkeson G.S., Silver R.M., Zeng X., Shi S., Sun L. Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice. Lupus, 2010 , vol. 19, pp. 1502-1514.

54. Haynesworth S.E., Baber M.A. Caplan A.I. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal Abs. Bone, 1992, vol. 13, pp. 69-80.

55. Hendrikx T.K., van Gurp E.A., Sewgobind V.D., Mol W.M., Schoordijk W., Klepper M., Velthuis J.H., Geel A., Ijzermans J.N. Weimar W., Baan C.C. Generation of donor-specific regulatory T-cell function in kidney transplant patients. Transplantation, 2009, vol. 87, pp. 376-383.

56. Horwitz E.M., Le Blanc K., Dominici M., Mueller I., Slaper-Cortenbach I., Marini F.C., Deans R.J., Krause D.S., Keating A. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy, 2005, vol. 7, pp. 393-395.

57. Hoshino A., Chiba H., Nagai K., Ishii G. Ochiai A. Human vascular adventitial fibroblasts contain mesenchymal stem/progenitor cells. Biochemical and Biophysica Research Communications, 2008, vol. 368, pp. 305-310.

58. Iwasaki, A., Kelsall, B.L. Localization of distinct Peyer’s patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3alpha, MIP-3beta, and secondary lymphoid organ chemokine. J. Exp. Med., 2000, vol. 191, pp. 1381-1394.

59. Ichii M., Oritani K., Yokota T., Schultz D.C., Holter J.L., Kanakura Y., Kincade P.W. Stromal cell-free conditions favorable for human B lymphopoiesis in culture. J. Immunol Meth., 2010, vol. 359, pp. 47-55.

60. Javazon E.H., Beggs K.J., Flake A.W. Mesenchymal stem cells: Paradoxes of passaging. Exp. Hematol., 2004, vol. 32, pp. 414-425.

61. Jori F.P., Napolitano M.A., Melone M.A., Jori F.P., Napolitano M.A., Melone M.A., Cipollaro M., Cascino A., Altucci L., Peluso G., Giordano A., Galderisi U. Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J. Cell Biochem., 2005, vol. 94, pp. 645-655.

62. Josefowicz S.Z., Lu L.F., Rudensky A.Y. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol., 2012, vol. 30, pp. 531-64.

63. Ju X., Clark G., Hart D.N. Review of human DC subtypes. Methods Mol Biol., 2010, vol. 595, pp. 3-20.

64. Kim D.H., Yoo K.H., Choi K.S., Choi J., Choi S.Y., Yang S.E., Yang Y.S., Im H.J., Kim K.H., Jung H.L., Sung K.W., Koo H.H. Gene expression profile of cytokine and growth factor during differentiation of bone marrowderived mesenchymal stem cell. Cytokine, 2005, vol. 31, 119-126.

65. Kim J., Hematti P. Mesenchymal stem cell-educated macrophages: A novel type of alternatively activated macrophages. Exp. Hematol., 2009, vol. 37, 1445-1453.

66. Klages K. Mayer C.T., Lahl K., Loddenkemper C., Teng M.W., Ngiow S.F., Smyth M.J., Hamann A., Huehn J., Sparwasser T. Selective depletion of FoxP3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res., 2010, vol. 70, pp. 7788-7799.

67. Komoda H., Okura H., Lee C.M., Sougawa N., Iwayama T., Hashikawa T., Saga A., Yamamoto-Kakuta A., Ichinose A., Murakami S., Sawa Y., Matsuyama A. Reduction of N-glycolylneuraminic acid xenoantigen on human adipose tissue-derived stromal cells / mesenchymal stem cells leads to safer and more useful cell sources for various stem cell therapies. Tissue Eng. Part A, 2010, vol. 16, pp. 1143-1155.

68. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood., 2003, vol. 101, pp. 3722-3729.

69. Krampera M., Cosmi L., Angeli R., Pasini A., Liotta F., Andreini A., Santarlasci V., Mazzinghi B., Pizzolo G., Vinante F., Romagnani P., Maggi E., Romagnani S., Annunziato F. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 2006, vol. 24, pp. 386-98.

70. Kucharzik T., Hudson J.T. 3rd, Waikel R.L., Martin W.D., Williams I.R. CCR6 expression distinguishes mouse myeloid and lymphoid dendritic cell subsets: Demonstration using a CCR6 EGFP knock-in mouse. Eur. J. Immunol., 2000, vol. 32, pp. 104-112.

71. Labastie M.C., Cort s F., Rom o P.H., Dulac C., P ault B. Molecular identity of hematopoietic precursor cells emerging in the human embryo. Blood, 1998, vol. 92, pp. 3624-3635.

72. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J. Immunol., 2003, vol. 57, pp. 11-20.

73. Lee O.K., Kuo T.K., Chen W.M., Lee K.D., Hsieh S.L., Chen T.H. Isolation of multi potent mesenchymal stem cells from umbilical cord blood. Blood, 2004, vol. 103, pp. 1669-1675.

74. Li H., Guo Z.K, Li X.S., Hou C.M., Tang P.H., Mao N. Functional and phenotypic alteration of intrasplenic lymphocytes affected by mesenchymal stem cells in a murine allosplenocyte transfusion model. Cell Transplant. 2007, vol. 16, pp. 85-95.

75. Li Y.P., Paczesny S., Lauret E., Poirault S., Bordigoni P., Mekhloufi F., Hequet O., Bertrand Y., Ou-Yang J.P., Stoltz J.F., Miossec P., Eljaafari A. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J. Immunol., 2008, vol. 180, pp. 1598-1608.

76. Liotta F., Angeli R., Cosmi L., Fili L., Manuelli C., Frosali F., Mazzinghi B., Maggi L., Pasini A., Lisi V., Santarlasci V., Consoloni L., Angelotti M.L., Romagnani P., Parronchi P., Krampera M., Maggi E., Romagnani S., Annunziato F. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells, 2008, vol. 26, pp. 279-289.

77. Liu W., Putnam A.L., Xu-Yu Z., Szot G. L., Lee M.R., Zhu S., Gottlieb P.A., Kapranov P., Gingeras T.R., Fazekas de St-Groth B., Clayberger C., Soper D.M., Ziegler S.F., Bluestone J.A. CD127 expression inversely correlates with FoxP 3and suppressive function of human CD4+Treg cells. J. Exp.Med., 2006, vol. 203, pp. 1701-1711.

78. Lombardo E., DelaRosa O., Mancheno-Corvo P., Menta R., Ramirez C., Buscher D. Toll-like receptormediated signaling in human adipose-derived stem cells: Implications for immunogenicity and immunosuppressive potential. Tissue Eng. Part A, 2009, vol. 15, pp. 1579-1589.

79. Lu X., Liu T., Gu L., Huang C., Zhu H., Meng W., Xi Y., Li S., Liu Y. Immunomodulatory effects of mesenchymal stem cells involved in favoring type 2 T cell subsets. Transpl. Immunol., 2009, vol. 22, pp. 55-61.

80. Lund F.E., Randall T.D. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nature Reviews Immunology, 2010, vol. 10, pp. 236-247.

81. Maby-El Hajjami H., Amé-Thomas P., Pangault C., Tribut O., DeVos J., Jean R., Bescher N., Monvoisin C., Dulong J., Lamy T., Fest T., Tarte K. Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase. Cancer Res., 2009, vol. 69, pp. 3228-3237.

82. Maccario R., Podestà M., Moretta A., Cometa A., Comoli P., Montagna D., Daudt L., Ibatici A., Piaggio G., Pozzi S., Frassoni F,. Locatelli F. Interaction of human mesenchymal stem cells with cells involved in alloantigenspecific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica, 2005, vol. 90, pp. 516-525.

83. Madec A.M., Mallone R., Afonso G., Abou Mrad E., Mesnier A., Eljaafari A., Thivolet C. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia. 2009, vol. 52, pp. 1391-1399.

84. Magatti M., De Munari S., Vertua E., Nassauto C., Albertini A., Wengler G.S., Parolini O. Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes. Cell Transplant., 2009, vol. 18, pp. 899-914.

85. Majesky M.W., Dong X.R., Hoglund V., Mahoney Jr. W.M., Daum G. The adventitia: a dynamic interface containing resident progenitor cells. Arteriosclerosis, Thrombosis, and Vascular Biology., 2011, vol. 31, pp. 1530-1539.

86. Majumdar M.K., Keane-Moore M., Buyaner D., Hardy W.B., Moorman M.A., McIntosh K.R. and Mosca J.D. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J. Biomed. Sci., 2002, vol. 10, pp. 228-241.

87. Masteller E.L., Warner M.R., Tang Q., Tarbell K.V., McDevitt H., Bluestone J.A. Expansion of functional endogenous antigen-specific CD4+ CD25+ regulatory T cells from nonobese diabetic mice. J. Immunol., 2005, vol. 175, pp. 3053-3059.

88. Masten B.J., Yates J.L., Pollard Koga A.M., Lipscomb M.F. Characterization of accessory molecules in murine lung dendritic cell function: Roles for CD80, CD86, CD54, and CD40L. Am. J. Respir. Cell Mol. Biol., 1997, vol. 16, pp. 335-342.

89. McIntosh K., Zvonic S., Garrett S., Mitchell J.B., Floyd Z.E., Hammill L., Kloster A., Di Halvorsen Y., Ting J.P., Storms R.W., Goh B., Kilroy G., Wu X., Gimble J.M. The immunogenicity of human adipose-derived cells: temporal changes in vitro. Stem Cells, 2006, vol. 24, pp. 1246-1253.

90. Meisel R., Zibert A., Laryea M., G bel U., D ubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation. Blood, 2004, vol. 103, pp. 4619-4621.

91. Montecino-Rodriguez E., Dorshkind K. B-1 B Cell Development in the Fetus and Adult. Immunity, 2012, vol. 36, pp. 13-21.

92. Morelli A.E., Thomson A.W. Dendritic cells: Regulators of alloimmunity and opportunities for tolerance induction. Immunol. Rev., 2003, vol. 196, pp. 125-146.

93. Morikawa S., Mabuchi Y., Kubota Y., Nagai Y., Niibe K., Hiratsu E., Suzuki S., Miyauchi-Hara C., Nagoshi N., Sunabori T., Shimmura S., Miyawaki A., Nakagawa T., Suda T., Okano H., Matsuzaki Y. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J. Exp. Med., 2009, vol. 206, pp. 2483-2496.

94. Musso A., Zocchi M.R., Poggi A. Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T-cell proliferation and B-cell survival. Haematologica, 2011, vol. 96, pp. 16-23.

95. Najar M., Raicevic G., Boufker H.I., Fayyad Kazan H., De Bruyn C., Meuleman N., Bron D., Toungouz M., Lagneaux L. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton’s Jelly and bone marrow sources. Cell Immunol., 2010, vol. 264, pp. 171-179.

96. Najar M., Rouas R., Raicevic G., Boufker H.I, Lewalle P., Meuleman N., Bron D., Toungouz M., Martiat P., Lagneaux L. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy., 2009, vol. 11, pp. 570-583.

97. Nauta A.J., Westerhuis G., Kruisselbrink A.B., Lurvink E.G., Willemze R., Fibbe W.E. Donorderived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood, 2006, vol. 108, pp. 2114-2120.

98. Nauta A.J., Kruisselbrink A.B., Lurvink E., Willemze R., Fibbe W.E. Mesenchymal stem cells inhibit generation and function of both CD34ю-derived and monocytederived dendritic cells. J. Immunol., 2006, vol. 177, 2080-2087.

99. Nemeth K., Leelahavanichkul A., Yuen P.S., Mayer, B., Parmelee A., Doi K., Robey P.G., Leelahavanichkul K., Koller B.H., Brown J.M., Hu X., Jelinek I., Star R.A., Mezey E. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med., 2009, vol. 15, pp. 42-49.

100. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int. J. Cancer, 2010, vol. 127, pp. 759-767.

101. Ohtaki H., Ylostalo J.H., Foraker J.E., Robinson A.P., Reger R.L., Shioda S., Prockop D.J. Stem/ progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc. Natl. Acad. Sci. U.S.A., 2008, vol. 105, pp. 14638-14643.

102. . Opitz C.A., Litzenburger U.M., Lutz C., Lanz T.V., Tritschler I., Koppel A., Tolosa E., Hoberg M., Anderl J., Aicher W.K., Weller M., Wick W., Platten M. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells., 2009, vol. 27, pp. 909-919.

103. Osterholzer J.J., Ames T., Polak T., Sonstein J., Moore B.B., Chensue S.W., Toews G.B., Curtis J.L. CCR2 and CCR6, but not endothelial selectins, mediate the accumulation of immature dendritic cells within the lungs of mice in response to particulate antigen. J. Immunol., 2005, vol. 175, pp. 874-883.

104. Oswald J., Boxberger S., Jorgensen B., Feldmann S., Ehninger G., Bornh user M., Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells., 2004, vol. 22, pp. 377-384.

105. Pevsner-Fischer M., Morad V., Cohen-Sfady M., Rousso-Noori L., Zanin-Zhorov A., Cohen S., Cohen I.R., Zipori D. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood, 2007, vol. 109, pp. 1422-1432.

106. Phinney D.G. Building a Consensus Regarding the Nature and Origin of Mesenchymal Stem Cells. J. Cell. Biochem., 2002, suppl. 38, pp. 7-12.

107. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science, 1999, vol. 284, pp. 143-147.

108. Popp F.C., Eggenhofer E., Renner P., Slowik P., Lang S.A., Kaspar H., Geissler E.K., Piso P., Schlitt H.J., Dahlke M.H. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl. Immunol., 2008, vol. 20, pp. 55-60.

109. Potian J.A., Aviv H., Ponzio N.M., Harrison J.S., Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular cellular responses to alloantigens and recall antigens. J. Immunol., 2003, vol. 171, pp. 3426-3434.

110. Prevosto C., Zancolli M., Canevali P., Zocchi M.R., Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica, 2007, vol. 92, pp. 881-888.

111. Rafei M., Hsieh J., Fortier S., Li M., Yuan S., Birman E., Forner K., Boivin M.N., Doody K., Tremblay M., Annabi B., Galipeau J.. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood, 2008, vol. 112, pp. 4991-4998.

112. Raffaghello L., Bianchi G., Bertolotto M., Montecucco F., Busca A., Dallegri F., Ottonello L., Pistoia V. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells, 2008, vol. 26, pp. 151-162.

113. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp. Cell Res., 2006, vol. 312, pp. 2169-2179.

114. Rasmusson I., Ringden O., Sundberg B., Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation, 2003, vol. 76, pp. 1208-1213.

115. Rasmusson I., Le Blanc K., Sundberg B., Ringden O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand. J. Immunol., 2007, vol. 65, pp. 336-343.

116. Romanov Y.A., Svintsitskaya V.A., Smirnov V.N. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells, 2003, vol. 21, pp. 105-110.

117. Romieu-Mourez R., Francois M., Boivin M.N., Bouchentouf M., Spaner D.E., Galipeau J. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J. Immunol., 2009, vol. 182, pp. 7963-7973.

118. Rossant J. Stem cells from the mammalian blastocyst. Stem Cells, 2001, vol. 19, pp. 477-482.

119. Ryan J.M., Barry F.P., Murphy J.M., Mahon B.P. Mesenchymal stem cells avoid allogeneic rejection. BMC J. Inflamm. (Lond), 2005, vol. 2, art. 8.

120. Sagaert X., De Wolf-Peeters C Classification of B-cells according to their differentiation status, their microanatomical localization and their developmental lineage. Immunology Letters, 2003, pp. 179-186

121. Sacchetti B., Funari A., Michienzi S., Di Cesare S., Piersanti S., Saggio I., Tagliafico E., Ferrari S., Robey P.G., Riminucci M., Bianco P. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell, 2007, vol. 131, pp. 324-336.

122. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol., 1995, vol. 155, pp. 1151-1164.

123. Sarugaser R., Lickorish D., Baksh D., Hosseini M.M., Davies J.E. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells, 2005, vol. 23, no. 2, pp. 220-229.

124. Schena F., Gambini C., Gregorio A., Mosconi M., Reverberi D., Gattorno M., Casazza S., Uccelli A., Moretta L., Martini A., Traggiai E. Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum., 2010, vol. 62, pp. 2776-2786.

125. Schraufstatter I.U., Discipio R.G., Zhao M., Khaldoyanidi S.K. C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J. Immunol., 2009, vol. 182, pp. 3827-3836.

126. Schu S., Nosov M., O’Flynn L., Shaw G., Treacy O., Barry F., Murphy M., O’Brien T., Ritter T. Immunogenicity of allogeneic mesenchymal stem cells. J. Cell. Mol. Med., 2011, pp. 1582-4934 doi:10.1111/j.

127. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., Solomon M., Selby W., Alexander S.I., Nanan R., Kelleher A., Fazekas de St Groth B. Expression of interleukin IL-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med., 2006, vol. 203, pp. 1693-700.

128. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., Borg C., Saas P., Tiberghien P., Rouas-Freiss N., Carosella E.D., Deschaseaux F. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFoxP3+ regulatory T cells. Stem Cells, vol. 2008, vol. 26, pp. 212-222.

129. Shevach E.M., Thornton A., Suri-Payer E. T lymphocyte-mediated control of autoimmunity. Novartis Found. Symp., 1998, vol. 215, pp. 200-211; discussion pp. 211-230.

130. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxevanis C.N., Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells., 2006, vol. 24, pp. 74-85.

131. Spaggiari G.M., Capobianco A., Abdelrazik H., Becchetti F., Mingari M.C., Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood, 2008, vol. 111, pp. 1327-1333.

132. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature. 2007, vol. 449, pp. 419-426.

133. Steinman, R.M., Nussenzweig, M.C. Avoiding horror autotoxicus The importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. U.S.A., 2002, vol. 99, pp. 351-358.

134. Stout R.D., Watkins S.K., Suttles J. Functional plasticity of macrophages: In situ reprogramming of tumorassociated macrophages. J. Leukoc. Biol., 2009, vol. 86, pp. 1105-1109.

135. Sun L., Akiyama K., Zhang H., Yamaza T., Hou Y., Zhao S., Xu T., Le A., Shi S. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells, 2009, vol. 27, pp. 1421-1432.

136. Suva D., Passweg J., Arnaudeau S., Hoffmeyer P., Kindler V. In vitro activated human T lymphocytes very efficiently attach to allogenic multipotent mesenchymal stromal cells and transmigrate under them. J. Cell Physiol. 2008 , vol. 214, no. 3, pp. 588-94.

137. Tabera S., P rez-Sim n J.A., D ez-Campelo M., S nchez-Abarca L.I., Blanco B., L pez A., Benito A., Ocio E., S nchez-Guijo F.M., Ca izo C., San Miguel J.F. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica, 2008, vol. 93, pp. 1301-1309.

138. Tallone T., Realini C., B hmler A., Kornfeld C., Vassalli G., Moccetti T., Bardelli S. Soldati G. Adult Human Adipose Tissue Contains Several Types of Multipotent Cells. J. Cardiovasc. Trans. Res., 2011, vol. 4, pp. 200-210.

139. Tang Q., Bluestone J.A. The FoxP3+ regulatory T cell: A jack of all trades, master of regulation. Nat. Immunol., 2008, vol. 9, pp. 239-244.

140. Tarnok A., Ulrich H., Bocsi J. Phenotypes of Stem Cells from Diverse Origin. Cytometry A, 2010, vol. 77, pp. 6-10.

141. Tavian M., Hallais M.F., P ault B. Emergence of intraembryonic hematopoietic precursors in the pre-liver human embryo. Development, 1999, vol. 126, pp. 793-803.

142. Tavian M., Zheng B., Oberlin E., Crisan M., Sun B., Huard J., Peault B. The vascular wall as a source of stem cells. Ann. N. Y. Acad. Sci., 2005, vol. 1044, pp. 41-50.

143. Tesar V. Monocyte ’reprogramming’ and mortality in septic patients with acute kidney injury. Blood Purif., 2008, vol. 26, pp. 186-187.

144. Tilki D., Hohn H. P., Ergun B., Rafii S., Ergun S. Emerging biology of vascular wall progenitor cells in health and disease. Trends in Molecular Medicine, 2009, vol. 15, pp. 501-509.

145. Tokcaer-Keskin Z., Akar A.R., Ayaloglu-Butun F., Terzioglu-Kara E., Durdu S., Ozyurda U., Ugur M., Akcali K.C. Timing of induction of cardiomyocyte differentiation for in vitro cultured mesenchymal stem cells: Aperspective for emergencies. Can. J. Physiol. Pharmacol., 2009, vol. 87, pp. 143-150.

146. Tomchuck S.V.L., Zwezdaryk K.J., Coffelt S.B., Waterman,R.S., Danka E.S., Scandurro A.B. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells, 2008, vol. 26, pp. 99-107.

147. Traggiai E., Volpi S., Schena F., Gattorno M., Ferlito F., Moretta L., Martini A. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells, 2008, vol. 26, pp. 562-569.

148. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation, 2003, vol. 75, pp. 389- 397.

149. Tu Z., Li Q., Bu H., Lin F. Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev., 2010, vol. 19, pp. 1803-1809.

150. Turnquist H.R., Thomson A.W. Taming the lions: Manipulating dendritic cells for use as negative cellular vaccines in organ transplantation. Curr. Opin. Organ Transplant., 2008, vol. 13, pp. 350-357.

151. Tyndall A., Walker U.A., Cope A., Dazzi F., De Bari C., Fibbe W., Guiducci S., Jones S., Jorgensen C., Le Blanc K., Luyten F., McGonagle D., Martin I., Bocelli-Tyndall C., Pennesi G., Pistoia V., Pitzalis C., Uccelli A., Wulffraat N., Feldmann M. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res. Ther., 2007, vol. 9, p. 301.

152. Uccelli A., Moretta L., Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur. J. Immunol., 2006, vol. 36, pp. 2566-2573.

153. van den Berk L.C., Roelofs H., Huijs T., Siebers-Vermeulen K.G., Raymakers R.A., Kogler G., Figdor C.G., Torensma R. Cord blood mesenchymal stem cells propel human dendritic cells to an intermediate maturation state and boost interleukin-12 production by mature dendritic cells. Immunology, 2009, vol. 128, pp. 564-572.

154. Waldmann H., Adams, E., Fairchild P., Cobbold S. Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol. Rev., 2006, vol. 212, pp. 301-313.

155. Wang Z.J., Zhang F.M., Wang L.S., Yao Y.W., Zhao Q., Gao X. Lipopolysaccharides can protect mesenchymal stem cells (MSCs) from oxidative stress-induced apoptosis and enhance proliferation of MSCs via Toll-like receptor(TLR)- 4 and PI3K/Akt. Cell Biol. Int. 2009, vol. 33, 665-674.

156. Wang Q., Sun B., Wang D., Ji Y., Kong Q., Wang G., Wang J., Zhao W., Jin L., Li H. Murine bone marrow mesenchymal stem cells cause mature dendritic cells to promote T-cell tolerance. Scand. J. Immunol., 2008,, vol. 68, pp. 607-615.

157. Youd M., Blickarz C., Woodworth L., Touzjian T., Edling A., Tedstone J., Ruzek M., Tubo R., Kaplan J., Lodie T. Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease. Clin. Exp. Immunol., 2010, vol. 161, pp. 176-186.

158. Yang M., Rui K., Wang S., Lu L. Regulatory B cells in autoimmune diseases. Cell. Mol. Immunol., 2013, vol. 10, pp. 122-132.

159. Zannettino A.C., Paton S., Arthur A., Khor F., Itescu S., Gimble J.M., Gronthos S. Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivo. J. Cell Physiol., 2008, vol. 214, no. 2, pp. 413-421.

160. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., Giunti D., Ceravolo A., Cazzanti F., Frassoni F., Mancardi G., Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 2005, vol. 106, pp. 1755-1761.

161. Zelenika D., Adams E., Humm S., Lin C.Y., Waldmann H., Cobbold, S.P. The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance. Immunol. Rev. 2001, vol. 182, pp. 164-179.

162. Zhang X. Regulatory functions of innate-like B cells. Cellular & Molecular Immunology, 2013, vol. 10, pp. 113-121.

163. Zhang Y., Li C., Jiang X., Zhang S., Wu Y., Liu B., Tang P., Mao N. Human placenta-derived mesenchymal progenitor cells support culture expansion of long-term culture-initiating cells from cord blood CD34+ cells. Exp. hematol., 2004, vol. 32, pp. 657-664.

164. Zhang B., Liu R., Shi D., Liu X., Chen Y., Dou X., Zhu X., Lu C., Liang W., Liao L., Zenke M., ZhaoR.C. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood, 2009, vol. 113, pp. 46-57.

165. Zhou K., Zhang H., Jin O., Feng X., Yao G., Hou Y., Sun L. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell. Mol. Immunol., 2008, vol. 6, pp. 417-424.

166. Zhu Y., Liu T., Song K., Fan X., Ma X., Cui Z. Adipose-derived stem cell: a better stem cell than BMSC. Cell Biochem. Funct., 2008, vol. 26, pp. 664-675.

167. Zimmerlin L., Donnenberg S., Pfeifer M.E., Meyer E.M., P ault B., Rubin J.P., Donnenberg A.D. Stromal vascular progenitors in adult human adipose tissue. Cytometry Part A, 2010, vol. 77, pp. 22-30.

168. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol., 2006, vol. 4, pp. 295- 307.


Для цитирования:


Климович В.Б. ИММУНОМОДУЛИРУЮЩАЯ АКТИВНОСТЬ МЕЗЕНХИМАЛЬНЫХ СТРОМАЛЬНЫХ (СТВОЛОВЫХ) КЛЕТОК. Медицинская иммунология. 2014;16(2):107-126. https://doi.org/10.15789/1563-0625-2014-2-107-126

For citation:


Klimovich V.B. IMMUNOMODULATORY ACTIVITY OF MESENCHIMAL STROMAL (STEM) CELLS. Medical Immunology (Russia). 2014;16(2):107-126. (In Russ.) https://doi.org/10.15789/1563-0625-2014-2-107-126

Просмотров: 1298


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1563-0625 (Print)
ISSN 2313-741X (Online)